Bristol Myers' Arlo-cel Hits Primary Endpoint in Phase 2 Multiple Myeloma Trial
BMY sits 53% above its 52-week low of $42.52 on light trading volume (0.3× avg).
Summary
Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlo-cel, its GPRC5D-directed CAR T therapy for heavily pretreated relapsed/refractory multiple myeloma. The study met its primary endpoint with a statistically significant overall response rate in patients with four or more prior lines of therapy, and also achieved key secondary endpoints including complete response rates. Safety was consistent with existing CAR T therapies. This is the first disclosure of these data and supports a potential first-in-class, single-infusion treatment option in a difficult-to-treat population. The company plans to present full results at an upcoming medical meeting. The news follows recent FDA accelerated approval of iberdomide for multiple myeloma and a voluntary pause of the Zola-Cel program, highlighting the company's active pipeline in this disease area.
At the time of this announcement, BMY was trading at $65.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $133B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.